Emerging POC Target InterVention Diagnostics for early access programs and pilot deployments of their handheld electrochemical analyzer to demonstrate rapid, single-drop blood chemistry testing in point-of-care settings within hospitals and clinics.

Diabetes Focus Leverage Jim Connolly's 30+ years of diabetes care sensor expertise to position partnerships with diabetes care providers, clinics, and DME suppliers for scalable blood test capabilities that reduce laboratory dependency.

Cost Advantage Highlight the potential for dramatically reduced test costs and faster results to healthcare systems, enabling sales conversations with hospital networks, urgent care centers, and patient-access programs seeking cost containment.

Regulatory Readiness Position readiness to navigate regulatory pathways with the existing team and patent-backed innovations to accelerate time-to-market, appealing to health systems prioritizing compliant, clinically validated point-of-care solutions.

Strategic Partnerships Pursue collaborations with larger medical device manufacturers and distributors (e.g., in contexts similar to Penumbra or AngioDynamics scale) to co-develop and distribute multi-parameter blood testing platforms.